Omeros/$OMER
1D1W1MYTD1Y5YMAX
Capital at risk
About Omeros
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
- Ticker
- $OMER
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 175
- Headquarters
- Seattle, United States
- Website
- www.omeros.com
Omeros Metrics
BasicAdvanced
$1.4B
12.12
$1.57
2.60
-
Price and volume
Market cap
$1.4B
Beta
2.6
52-week high
$21.24
52-week low
$4.06
Average daily volume
1.6M
Financial strength
Current ratio
1.951
Quick ratio
1.614
Long term debt to equity
-4.626
Total debt to equity
-5.781
Interest coverage (TTM)
-3.25%
Profitability
EBITDA (TTM)
-71.913
Gross margin (TTM)
-18.14%
Net profit margin (TTM)
324.88%
Operating margin (TTM)
-189.53%
Effective tax rate (TTM)
1.77%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-18.68%
Return on equity (TTM)
-83.23%
Valuation
Price to earnings (TTM)
12.118
Price to revenue (TTM)
34.867
Price to book
-26.73
Price to tangible book (TTM)
-26.73
Price to free cash flow (TTM)
7.822
Free cash flow yield (TTM)
12.78%
Free cash flow per share (TTM)
2.434
Growth
Earnings per share change (TTM)
-174.52%
10-year revenue growth (CAGR)
3.45%
3-year earnings per share growth (CAGR)
34.79%
10-year earnings per share growth (CAGR)
-1.89%
What the Analysts think about Omeros
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Analyst projections of the future price of Omeros stock.
Bulls say / Bears say
YARTEMLEA’s first full commercial quarter produced $28.5 million of net sales, up 188% sequentially, with 73 ordering accounts and $4.1 million of operating cash flow. The launch therefore reached operating break-even quickly, suggesting early physician adoption is translating into real cash generation. (Omeros, Exa Markets)
US reimbursement infrastructure is improving: YARTEMLEA’s permanent J-code took effect on 1 July, while CMS’s new technology add-on payment is due to begin on 1 October. These changes should make hospital billing easier and improve access for eligible inpatient cases. (Omeros, MarketBeat)
YARTEMLEA’s European expansion has suffered a major setback: the EMA’s CHMP adopted a negative opinion on the marketing application. Omeros has requested re-examination, but approval remains uncertain and the process has no guaranteed outcome. (Omeros, Financial Times)
Near-term revenue is heavily dependent on one recently launched product, and management has declined to provide revenue guidance while it gains more experience with prescribing trends and patient demand. The strong second quarter may therefore not yet prove that the launch rate is durable. (Exa Markets, TradingKey)
Liquidity is less comfortable after Omeros spent $60.2 million in July to repurchase convertible notes: $132.0 million of cash and investments was reported immediately before that transaction, while $40.3 million of debt remained afterwards. Although quarterly operating cash flow turned positive, the company still has to fund commercial expansion and several development programmes. (Omeros, TradingKey)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
Omeros Financial Performance
Revenues and expenses
Omeros Earnings Performance
Company profitability
Upcoming events
No upcoming events
Omeros News
AllArticlesVideos
Funds containing Omeros
AllUSDGBPEUR
Fund name | Fund size | $OMER weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.09% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.